<DOC>
	<DOCNO>NCT01647672</DOCNO>
	<brief_summary>Select 60 case woman breast cancer clinical stage T1-4N0-2M0 . Then treat 4 cycle TAC ( Abraxane 260mg/m2 , EPI 60 mg/m2 , CTX 500 mg/m2 , 21day/cycle ) neoadjuvant chemotherapy . Finally investigator assess efficacy safety Albumin-bound Paclitaxel .</brief_summary>
	<brief_title>Efficacy Safety With Albumin-bound Paclitaxel ( Abraxane ) TAC Neoadjuvant Chemotherapy Breast Cancer</brief_title>
	<detailed_description>The investigator select 60 case woman breast cancer clinical stage T1-4N0-2M0 . Then treat 4 cycle TAC ( Abraxane 260mg/m2 , EPI 60 mg/m2 , CTX 500 mg/m2 , 21day/cycle ) neoadjuvant chemotherapy . Finally investigator assess efficacy safety Albumin-bound Paclitaxel .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Karnofsky ≥ 70 2 . Provision inform consent 3 . Pathological confirmation breast cancer 4 . Tumor stage ( TNM ) : T24bN03M0 5 . Measurable disease per RECIST criterion 6 . Not previously treat radiotherapy , chemotherapy biological therapy . 7 . Laboratory criterion : PLT ≥ 100*109/L WBC ≥ 4000/mm3 HGB ≥ 10g/dl GOT , GPT , ALP ≤ 2*ULN TBIL , DBIL , CCr ≤ 1.5*ULN 1 . Pregnant woman 2 . History organ transplantation 3 . With mental disease 4 . With severe infection active gastrointestinal ulcer 5 . With severe liver disease ( cirrhosis ) , kidney disease , respiratory disease diabetes 6 . Diseasefree period malignant tumor le 5 year ( except cure basal cell skin cancer cervical carcinoma situ ) 7 . With heart disease 8 . Experimental drug allergy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>